Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

How the innovative use of data is transforming clinical research

2
March 2022

Dr. Dilshat Djumanov, Director of Data Science at Richmond Pharmacology, outlined the evolution of data management in clinical research and how this aids faster results and greater efficiencies.

View Article

The future of clinical workforce training programmes, an exclusive interview with MedCity

30
November 2021

Ulrike Lorch discusses the future of clinical workforce training programmes in an exclusive interview with MedCity

View Article

Richmond Pharmacology’s Dr Emma Akuffo joins fellow EUCROF task force members as a finalist at TOPRA Awards 2021

17
November 2021

EUCROF task force members compete for a prize at the TOPRA Awards 2021

View Article

Dr Ulrike Lorch joins the leadership team at the Faculty of Human Pharmacology

3
November 2021

Richmond Pharmacology’s Medical Director, Dr Ulrike Lorch, has been appointed Director of Human Pharmacology for the Faculty of Pharmaceutical Management (FPM). 

View Article

Developing talent in the fast-changing clinical research environment

2
November 2021

In a feature article for PharmaTimes, Dr. Ulrike Lorch, Medical Director at Richmond Pharmacology, outlines how investing in the clinical research workforce is crucial to delivering high quality, cutting-edge trials and achieving faster drug development

View Article

Focal epilepsy treatment progresses following positive Phase IIb results

26
October 2021

Richmond Pharmacology’s research partner, Xenon Pharmaceuticals reported positive top line results from its Phase IIb X-TOLE clinical trial of XEN1101 – a differentiated Kv7 potassium channel modulator.

View Article

Latest news

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event